Comedian Rob Schneider called on parents, coaches, and biologically female athletes to “refuse to play against” biologically male trans athletes, saying this “s*** has to stop.”

The 59-year-old actor tweeted on Thursday to his 1.5 million followers a clip of North Carolina high school female volleyball star Payton McNabb who was spiked in the face by a trans-identifying male player in a game and suffered a concussion and more.

“This s*** has to stop…,” Schneider said. “If the parents, coaches and ‘women’ athletes ALL REFUSE TO PLAY against these MEN…”

“It ALL STOPS!” he added.

This shit has to stop…
If the parents, coaches and ‘women’ athletes ALL REFUSE TO PLAY against these MEN…
It ALL STOPS! 🛑 ✋ https://t.co/qiXpEyvAeG

— Rob Schneider (@RobSchneider) April 20, 2023

“The Animal” star’s post included a tweet from former swimming champion Riley Gaines who’s made headlines for speaking out against making females compete against biological males in sports. Gaines is a former University of Kentucky star who was deprived of an NCAA award by biological male trans-identifying swimmer Lia Thomas.

“Watch the clip of Payton McNabb getting spiked in the face by a male competing with the women,” Gaines tweeted. “Then watch her testimony she gave today for the first time publicly.”

“I was honored to stand alongside her in NC to continue the fight to protect women’s sports,” she added.

In the video, McNabb said she still suffers today after the gruesome injuries she endured and spoke about how “dangerous” it is to allow biological males to compete against biological females in women’s sports.

“Other injuries I still suffer from today include impaired vision, partial paralysis on my right side, constant headaches as well as anxiety and depression,” McNabb said. “My ability to learn, retain, comprehend has also been impaired and I require accommodations at school for testing because of this.”

The former “Saturday Night Live” star recently talked about leaving the Democratic party because he said they are becoming more and more extreme in their views, as previously reported.

“It shouldn’t be such a shock. We don’t get ten parties, you get two,” Schneider said. “And I really feel like I don’t want the Democratic Party trying to run my life. And there’s not one aspect of your life that they don’t want to interfere with. So I had it with them. So I got out of California and moved to the slightly freer state of Arizona.”

Related: Rob Schneider Reveals The Moment He Knew ‘Saturday Night Live’ Was ‘Over’

The FDA approved a the use of a drug combination that represents the first approved therapy in roughly 20 years for patients newly-diagnosed with diffuse large B-cell lymphoma, the non-Hodgkins lymphoma most prevalent in the U.S.

The drug Polivy in combination with Rituxan (rituximab), cyclophosphamide, doxorubicin and prednisone (R-CHP) was approved on Wednesday, The combination had been approved in 2019 for use but only for patients who had undergone two prior therapies.

“It has been nearly 20 years since a new treatment option has become available to people newly diagnosed with diffuse large B-cell lymphoma,” said Dr. Levi Garraway, chief medical officer and head of global product development for Genentech, which manufactures Polivy. “Today’s decision from the FDA to approve Polivy in combination with R-CHP in this setting brings a much-needed new treatment option which may improve outcomes and bring other benefits to many patients with this aggressive lymphoma.”

A study found that roughly 28 months after the combination was administered, a 27% reduction in the risk of disease production or death for patients occurred compared to patients who received standard of care.

“The FDA’s decision gives newly diagnosed patients with this aggressive form of lymphoma their first new treatment option in nearly two decades,” Lee Greenberger, Ph.D., Chief Scientific Officer of The Leukemia & Lymphoma Society, stated. “One of our major goals at LLS is to support science that moves us toward less toxic, and more effective treatment options, and this drug combination is a step in that direction.”

“While this new drug is a valuable addition for some patients, we need to keep pressing forward to find even better options for DLBCL and every type of blood cancer,” Greenberger added. “But advances like polatuzumab are important, not just for today’s patients, but because science builds on itself, helping us to learn more about effective use of target drugs and harnessing the immune system to help tomorrow’s patients do even better.”

“I believe this gain in progression-free survival is clinically meaningful for patients, and also leads to a reduction in the need for subsequent therapy,” Grzegorz Nowakowski, MD, of the Mayo Clinic Comprehensive Cancer Center in Rochester, Minnesota, said.